There are 383 resources available
70P - Adherence to treatment recommendations from multidisciplinary tumor boards
Presenter: Julia Roeper
Session: Poster Display session
71P - Predictors of anxiety and depression among advanced lung cancer patients attending palliative care department: An experience from the rural cancer centre
Presenter: Chaitanya Patil
Session: Poster Display session
72P - The risk factors of developing severity in immune checkpoint inhibitors-related pneumonitis in advanced lung cancer patients
Presenter: Yao Zhang
Session: Poster Display session
73P - A novel nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
Presenter: Sophie cao
Session: Poster Display session
74TiP - Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC
Presenter: Yi-Long Wu
Session: Poster Display session
76TiP - RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial
Presenter: Melissa Johnson
Session: Poster Display session
77TiP - TRUST-II: A global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumors
Presenter: Misako Nagasaka
Session: Poster Display session
78TiP - Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase 1/2 ARROS-1 study
Presenter: Benjamin Besse
Session: Poster Display session
79TiP - A Phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Presenter: Frans Opdam
Session: Poster Display session